Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the ...

Grifols (NASDAQ:GRFS) has commenced discussions with banks to refinance its bonds due in 2025, Bloomberg News reported, a day ...

European markets were higher Thursday, rallying after a day in the doldrums during the previous session. The pan-European ...

The Spanish pharmaceutical company said it considered Brookfield’s offer of 10.50 euros a share undervalued the company and ...

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield ...

Fortress is offering 310p per share, valuing the total equity of the company at around £338 million ($428 million; €406 ...

For Spain’s billionaire Grifols family, which turned a blood-collection business into one of the world’s largest medical ...

The Canadian fund Brookfield has decided to withdraw its interest in a public exclusion offer to acquire Grifols due to ...

Barcelona-based Grifols has seen its stock value plummet since January, when short seller Gotham City Research accused the company of manipulating debt and earnings reporting by consolidating profit ...

Grifols said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks ...

Plus, Brookfield drops deal for Spanish healthcare group Grifols and Sequoia Capital’s spun-off China unit hunts for global deals ...